In type I familial amyloid polyneuropathy (FAP) caused by a variant Met3O-transthyretin (TTR), genetic anticipation has been reported. To determine whether anticipation of the disease is a true biological phenomenon or the result of ascertainment bias, we compared age at onset of the affected child with that of the affected parent in 68 parent-child pairs (including data on assumed age at onset and on asymptomatic obligate heterozygotes and parents at obligate 50% risk) in 15 families. Excluding the parent-child pairs involving the proband and "bilineal pairs", onset occurred earlier in the child than in the transmitting parent in 60 out of 68 "unilineal pairs". After correction for ascertainment bias resulting from incomplete penetrance and reduced biological fitness in early onset patients, the number of anticipation pairs (60 pairs) was still significantly larger than that of nonanticipation pairs (29.7 pairs) (p<0.05). When the children were sons, the difference in age at onset was significantly greater in the mother-son pairs than in the father-son pairs (p=0.023). Although not all ascertainment biases could be eliminated, these data show strong evidence that anticipation in the transmission of Met3O-TTR FAP is a true biological phenomenon. (JMed Genet 1998;35:23-30) 
The transthyretin (TTR) amyloidoses are the most prevalent type of hereditary systemic amyloidoses exhibiting an autosomal dominant pattern.' 2 Peripheral neuropathy is the major clinical manifestation of some TTR amyloidoses, and the syndrome is named familial amyloid polyneuropathy (FAP). There are now approximately 60 known variants of TTR.2 A disorder caused by a variant TTR with a substitution of methionine for valine at position 30 (Met3O-TTR)3 causes a lethal systemic amyloidosis characterised by progressive polyneuropathy and autonomic failure. The disorder has to date been called type I FAP. This type of TTR amyloidosis is the most common and patients are widely distributed in the world. 4 The age at onset of type I FAP is variable, ranging from the second decade to the seventh decade and penetrance is incomplete.5 6 Thus, some unknown factor(s), environmental or genetic or both, other than the Met3O-TTR mutation is involved in determination of the age at onset.
The clinical observation of anticipation, which means earlier onset and a more severe clinical picture in successive generations, has been noted in a number of hereditary disorders, such as Huntington's disease (HD),7 myotonic dystrophy (DM),8 spinocerebellar ataxia type 1 (SCA1),9 bipolar affective disorder,'" polycystic kidney disease, " leukaemia," and facioscapulohumeral muscular dystrophy. '3 '4 In some of these (including HD, DM, and SCA1), increasing size of a trinucleotide repeat in successive generations is presumed to be the molecular basis for the anticipation."' An anticipation phenomenon has also been reported in type I FAP patients originating from Portuguese,'6"' Swedish,"
and some Japanese (Kumamoto prefecture and its vicinity)20 kindreds, but ascertainment bias such as described by Penrose2' for DM was not sufficiently eliminated in these reports. In contrast to "triplet repeat diseases", one base substitution in the TTR gene is responsible for the development of Met30-TTR FAP or type I FAP, and this gene abnormality cannot solely explain the anticipation. It is, therefore, important to clarify whether the anticipation in Met3O-TTR FAP is a true biological phenomenon or a result of ascertainment bias. In the present study, we suggest that anticipation in the FAP families with a Met3O-TTR gene abnormality may really occur.
Materials and methods

FAMILIES AND CLINICAL DIAGNOSIS
There are two large foci of type I FAP in Japan:
Kumamoto"2 and Nagano prefectures.23 24 We calculated the difference in ages at onset between the females and the males, using Student's t test. The difference in age at onset between the parents and the children was calculated and to ascertain the significance of the observed anticipation, a chi-square test for goodness of fit was used. Between unilineal and bilineal pairs, the differences in age at onset between the parents and the children were compared, using two sample t test with Welch's correction. Furthermore, the differences in age at onset between the parents and the children were compared between groups divided according to the sex of the parent or child, using Student's t test.
Results
AGE AT ONSET IN PARENT-CHILD PAIRS AND ANTICIPATION
We tried to examine all 38 families, each of them including at least one patient with the Met30-TTR mutation. However, it soon became clear that it was impossible to obtain sufficiently large pedigrees for all families, since many members lived too far from Nagano prefecture, refused to cooperate, or had died. Moreover, it was very difficult to confirm the ages at onset of patients who died many years ago, even if we had information on their ages at death, because their relatives could not recall the precise year of the patients' onset of symptoms. In addition, since it was, at the earliest, after 1968 that the disease entity of FAP was recognised in Japan,22 almost no medical records of patients of older generations were useful.
Finally, we were able to obtain information on 15 families which included many patients with verified or presumed age at onset (fig 1) . These families did not include two patients homozygous for the Met30-TTR mutation, because no apparent symptoms had developed in their parents and children. 25 Since the pedigree study proved that ancestors of three probands were related to one another (in family 8), the 15 families included 17 probands. Comparing the data on the probands of these families (n= 17, five females and 12 males) with those on the probands of all the other type I FAP families (including probands in whom the Met30-TTR mutation was not verified, n=35, 13 females and 22 males) excluding sporadic patients, no significant difference was found for age at onset (mean 33.8 years (SD 12.9), mean 38.1 years (SD 11.7), Student's t test, p=0.121) or sex (df=1, X2=0.302). However, mean age at onset of sporadic patients (n=5, three females and two males, mean 57.2 years (SD 9.7)) was higher than that of the other two groups.
In these 15 families, ages at onset were verified in 69 patients (28 (SD 11.8) ) (the probands were included). We identified 70 unilineal and 11 bilineal affected parent-child pairs. Excluding 15 pairs involving a proband from unilineal pairs, we were left with 55 unilineal pairs. In 47 out of 55 unilineal pairs (85.5%), the children had an earlier onset than their transmitting parent (table 2B). In six of 47 pairs, the difference in age at onset was within two years (in six pairs, ages at onset of five parents and two children were assumed). The mean difference in age at onset was 10.7 years (SD 11.1) (range -15-+34 years). In eight bilineal pairs which did not involve probands, all children had an earlier onset than their transmitting parent. The mean difference in age at onset was 10.0 years (SD 4.4) (range +4-19 years). Between unilineal and bilineal pairs, no significant difference was found for the differences in age at onset between parents and children (p=0.373).
Furthermore, incorporating asymptomatic obligate heterozygotes into the analysis (one of them was alive and the others were dead), eight pairs with affected offspring apart from probands could be added. Since the present age of the living parent or age at death of the dead parent was higher than the age at onset of the affected child in each pair, we regarded these eight pairs as showing anticipation. Three couples of ancestors at obligate 50% risk, who had been asymptomatic through life and had died of other causes, had five affected children. The ages at death of both parents were higher than the age at onset of the child in all cases, so that five further pairs showing anticipation were added. Thus, we found a significantly larger number of pairs showing anticipation than those that did not ( (table 2D) . To account for ascertainment bias owing to reduced biological fitness in early onset patients, the number of additional children who would have been born to such patients if they had had normal fertility was estimated, using the average number of children born to unaffected sibs in 15 families (table 4) . This was tested on the females born before 1948 and the males born before 1945, whose children's mean age would have been 20 years or over in 1995. Since the number of children per head of the Japanese population decreased considerably after World War II, we divided the patients and unaffected sibs into two groups by the year of birth (after 1915 and in or before 1915). When the age at onset was 40 years or over, the fertility of female and male patients was higher than that of the normal sibs in both groups, but below 40 years, it was lower except for a female patient who was born in or before 1915. Fifteen female patients who were born after 1915 and had an onset below 40 would have had 13.6 more children if their fertility had been normal: ((2.04-1.50)x2+(2.04-1.50)x4+2.04x4+(2.04-1.60)x5). Similarly, in the males with an onset below 40 years, 13 patients who were born after 1915 would have had 9.8 more children: (2.00x1+(2.00-1.17)x7+(2.00-1.00)xl+(2.00-1.75)x4), and five patients who were born in or before 1915 would have had 6.0 more children: ((3.80-3.00)x 1 +(3.80-2.33)x3+(3.80-3.00)x 1). Thus, assuming normal fertility, the other 29.4 children would have been born into these families, and half of them (14.7 children) would have carried the abnormal gene. If disease onset in these additional children occurred randomly, since the age at onset of their parents was relatively low (below 40), most of the parent-child pairs could be classified as non-anticipation pairs. Thus, we added 14.7 pairs to the non-anticipation pairs (table 2E). After correction of bias, the number of anticipation pairs was still significantly larger than that of non-anticipation pairs with chisquare test for goodness of fit (X'=5.27, p<0.05).
SEX INFLUENCE
In table 5 the differences in age at onset are recorded according to the sex of parents and children (including data assumed from the age at death). The mean difference in ages at onset was greater in the pairs with a transmitting mother than in the pairs with a transmitting father, but not significantly (Student's t test, p=0.082). When the children were sons, however, the difference in age at onset was sig- Table 5 nificantly greater in the mother-son pairs than in the father-son pairs (p=0.023). Furthermore, the difference in age at onset was significantly greater on transmission to sons than to daughters (p=0.048).
Discussion
Our study showed that the anticipation observed in type I Met3O-TTR FAP families in Japan cannot be solely explained by ascertainment bias. However, some points should be considered in this study before drawing a conclusion. First, although in 69 patients the age at onset was decided on the basis of objective findings or subjective histories or both, in 47 other patients the age at onset was assumed from the age at death. Did this assumption cause a bias towards the result of anticipation? In our study, most of the patients for whom we could verify the age at onset were in relatively young generations and most of the patients whose age at onset could not be verified were in relatively old generations. Since the duration of survival after onset of type I FAP has generally become longer because of advances in treatment, in most of the patients for whom we could not verify the age at onset, the actual age at onset may have been higher than that assumed from age at death. Indeed, in the examination of the parent-child pairs with verified age at onset, all children fell ill earlier in life than their transmitting parent (table 2A) . Compared to this, with the addition of assumed data, some children had a later onset than their affected parent (table 2B) and the mean difference in age at onset between the parents and children became smaller. Accordingly, assuming the age at onset does not seem to be responsible for the result that substantiated the anticipation.
Second, as age at onset was later in life, the mean duration of survival after onset was shorter in female patients, but longer in male patients ( (table 1) , progression of the disease is generally rapid and steady. Therefore, there seems to be no large error in deciding the age at onset and we assumed the error was at most two years. Adding assumed ages at onset, the difference in age at onset between parents and children was within two years in six of 47 anticipation pairs, and it may be questionable whether these six pairs should be included in the anticipation group or not. However, in five out of six pairs, the parent's age at onset was assumed from the age at death, and then the actual difference in age at onset may be rather larger than the assumed difference because of the above mentioned reason.
Fourth, we excluded pairs involving the proband to eliminate bias towards apparent anticipation, but included pairs involving sibs of the proband or of the affected parent as the child, which may also tend to cause bias towards apparent anticipation. If they were excluded, our remaining data would be too few for analysis and more patients would be required. However, in large families with many patients ascertained, the patients in older generations who could produce several offspring should have a relatively later onset. Conversely, the patients in older generations who could produce no or a very small number of offspring because of early onset may be difficult to enter into the analysis. The missing data will cause bias towards apparent anticipation and cannot be compensated for, even though the additional children who would have been born to early onset patients in this study if they had had normal fertility were included. Thus, retrospective study of lethal disorders with reduced fertility harbours intrinsic ascertainment bias which is difficult to eliminate completely. Although collection of prospective data will be required, our study strongly suggests that anticipation in the transmission of Met3O-TTR FAP is a true biological phenomenon.
There was no significant difference in the age at onset between the probands of 15 families included in this study and the probands of type I FAP families not included. In comparison with these two groups, sporadic patients had a higher age at onset. This agrees with the previous suggestion that patients with Met3O-TTR FAP whose parents were both unaffected had a later age at onset.27 If 
